CN113367191B - 用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 - Google Patents
用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 Download PDFInfo
- Publication number
- CN113367191B CN113367191B CN202011348882.2A CN202011348882A CN113367191B CN 113367191 B CN113367191 B CN 113367191B CN 202011348882 A CN202011348882 A CN 202011348882A CN 113367191 B CN113367191 B CN 113367191B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- milk
- composition
- blood pressure
- regulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 46
- 230000001105 regulatory effect Effects 0.000 title abstract description 36
- 230000036772 blood pressure Effects 0.000 title abstract description 24
- 230000003647 oxidation Effects 0.000 title abstract description 22
- 238000007254 oxidation reaction Methods 0.000 title abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 239000000839 emulsion Substances 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 241000218587 Lactobacillus paracasei subsp. paracasei Species 0.000 claims abstract description 7
- 238000004321 preservation Methods 0.000 claims abstract description 3
- 238000000855 fermentation Methods 0.000 claims description 39
- 230000004151 fermentation Effects 0.000 claims description 39
- 230000003078 antioxidant effect Effects 0.000 claims description 29
- 235000015140 cultured milk Nutrition 0.000 claims description 29
- 235000013336 milk Nutrition 0.000 claims description 17
- 239000008267 milk Substances 0.000 claims description 17
- 210000004080 milk Anatomy 0.000 claims description 17
- 239000000047 product Substances 0.000 claims description 15
- 235000013361 beverage Nutrition 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- 239000006228 supernatant Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000002537 cosmetic Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 235000020122 reconstituted milk Nutrition 0.000 claims description 2
- 235000020247 cow milk Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 239000000126 substance Substances 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 4
- -1 feed Substances 0.000 abstract description 4
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 36
- 239000003963 antioxidant agent Substances 0.000 description 25
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 20
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 20
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 18
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 18
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 18
- 229940108924 conjugated linoleic acid Drugs 0.000 description 18
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 18
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 18
- 235000019156 vitamin B Nutrition 0.000 description 16
- 239000011720 vitamin B Substances 0.000 description 16
- 102000019197 Superoxide Dismutase Human genes 0.000 description 15
- 108010012715 Superoxide dismutase Proteins 0.000 description 15
- 238000000034 method Methods 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 9
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 8
- 230000007760 free radical scavenging Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 229930003270 Vitamin B Natural products 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 235000020124 milk-based beverage Nutrition 0.000 description 6
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 5
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 108010016268 hippuryl-histidyl-leucine Proteins 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 235000008939 whole milk Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000021001 fermented dairy product Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 229940079877 pyrogallol Drugs 0.000 description 3
- 235000020185 raw untreated milk Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000006701 autoxidation reaction Methods 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 235000020121 low-fat milk Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000013494 PH determination Methods 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 241001327916 Termitomyces albuminosus Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 229910001447 ferric ion Inorganic materials 0.000 description 1
- 229910001448 ferrous ion Inorganic materials 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000009438 liyan Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 229940099596 manganese sulfate Drugs 0.000 description 1
- 239000011702 manganese sulphate Substances 0.000 description 1
- 235000007079 manganese sulphate Nutrition 0.000 description 1
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000006395 oxidase reaction Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000006864 oxidative decomposition reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005080 plant death Effects 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
- A23L2/382—Other non-alcoholic beverages fermented
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Anesthesiology (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Birds (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明提供了用于抗氧化、调节血压的副干酪乳杆菌K56及其应用。本发明首先提供了副干酪乳杆菌(Lactobacillus paracasei subsp.paracasei)K56在制备具有抗氧化、调节血压和/或调节睡眠功效的组合物中的应用,所述副干酪乳杆菌的保藏编号为CGMCC No.15139或DSM27447。本发明研究发现,该副干酪乳杆菌菌株发酵乳液具有抗氧化、调节血压、调节睡眠等方向的应用,可广泛应用于食品、医药、饲料、化工等领域。
Description
技术领域
本发明涉及微生物发酵技术领域,尤其是涉及一种副干酪乳杆菌(Lactobacillusparacasei subsp.paracasei)K56(保藏编号CGMCC No.15139或DSM27447)发酵制备具有抗氧化、调节血压和/或调节睡眠功效的组合物中的相关应用。
背景技术
老化是人体器官最大的杀手,身体所产生的自由基(free radicals)则是造成器官老化的重要元凶。当身体调节自由基的机转丧失或失衡,过量的自由基产生则会破坏细胞DNA,改变细胞内蛋白质结构,攻击细胞膜,最后导致体细胞的死亡。皮肤老化也是因为长时间暴露于紫外线(UV exposure)或热源(heat exposure)下,诱发活性氧的量急剧增多,导致皮肤暗沉、皮肤癌等疾病。
高血压,与高血脂、高血糖统称为“三高”,是危害人类健康的一种心脑血管疾病。据专家推测,2025年全球范围的高血压患者人数将超过15亿。有效治疗或预防高血压疾病已成为一个全世界范围的健康问题。目前在体现降血压功效的发酵乳制品相关研究及产品主要集中在功能性成分物质的简单添加及应用。
从上世纪90年代开始,有关微生物尤其是乳酸菌的抗高血压研究受到高度重视,已有相关文献报道乳酸菌可降低血清胆固醇浓度、提高血清中SOD活性,降低过氧化脂质水平,具有辅助降血压血脂及抗氧化的功能,但是乳酸菌的这种辅助降血压血脂及抗氧化功能存在菌种甚至菌株的差异性,应用在具体的发酵乳制品中其功效有待进一步考证。
发明内容
本发明的一个目的在于提供副干酪乳杆菌K56的新用途。
副干酪乳杆菌(Lactobacillus paracasei subsp.paracasei)K56菌株已于2013年6月27日保存于德国微生物及细胞培养物收集中心(German Collection ofMicroorganisms and Cell Cultures),保藏编号DSM27447;另外,副干酪乳杆菌(Lactobacillus paracasei subsp.paracasei)K56菌株也已于2017年12月29日保存于中国微生物菌种保藏管理委员会普通微生物中心(China General MicrobiologicalCulture Collection Center,CGMCC),保藏编号CGMCC No.15139。
本发明发现副干酪乳杆菌(Lactobacillus paracasei subsp.paracasei)K56以主要含有乳成分的料液(乳基质)作为发酵底物,发酵产物中具有超氧化物歧化酶、血管紧张素转化酶抑制物、γ-氨基丁酸、共轭亚油酸、B族维生素等物质,具有优异的总抗氧化(T-AOC)能力,具有抗氧化、调节血压和/或调节睡眠功效。
从而,本发明提供了副干酪乳杆菌(Lactobacillus paracaseisubsp.paracasei)在制备具有抗氧化、调节血压和/或调节睡眠功效的组合物中的应用,所述副干酪乳杆菌的保藏编号为CGMCC No.15139或DSM27447。
根据本发明的具体实施方案,本发明的应用中,副干酪乳杆菌是通过发酵产生超氧化物歧化酶、血管紧张素转化酶抑制物、γ-氨基丁酸、共轭亚油酸和/或B族维生素而具有抗氧化、调节血压和/或调节睡眠功效。
根据本发明的具体实施方案,本发明的副干酪乳杆菌在制备具有抗氧化、调节血压和/或调节睡眠功效的组合物中的应用中,所述组合物可以为食品组合物、饲料组合物、化妆品组合物或药品组合物。
根据本发明的具体实施方案,本发明的应用中,利用副干酪乳杆菌CGMCCNo.15139或DSM27447发酵,制备得到发酵产物,得到的发酵产物作为或进一步用于制备所述具有抗氧化、调节血压和/或调节睡眠功效的组合物。
根据本发明的具体实施方案,本发明中,发酵时所用的发酵底物可以为乳液。优选地,所述乳液为可以为生鲜牛乳或是复原乳,可以是全脂乳、低脂乳或脱脂乳。所述乳液中,可以选择性地含有5%~10%的蔗糖。
根据本发明的具体实施方案,本发明中,所述发酵条件为:35℃~45℃,发酵1天~7天。
根据本发明的具体实施方案,本发明中,副干酪乳杆菌以种子液的形式接种于发酵底物中,接种量2%~5%。所述种子液的制备可以参照益生菌领域的常规技术进行。
根据本发明的具体实施方案,本发明中,作为副干酪乳杆菌K56的发酵底物的乳基质,可以是牛乳(全脂乳、低脂乳或脱脂乳)含量80%以上的乳液,其中可以根据需要选择性地添加甜味剂、稳定剂等辅料,例如可以是发酵乳或乳饮料制备过程中常用的发酵底物,本发明的副干酪乳杆菌K56发酵这些乳基质均可实现产生超氧化物歧化酶、血管紧张素转化酶抑制物、γ-氨基丁酸、共轭亚油酸和/或B族维生素等。
超氧化物歧化酶(Superoxide Dismutase,SOD)是生物体内存在的一种抗氧化金属酶,它能够催化超氧阴离子自由基歧化生成氧和过氧化氢,在机体氧化与抗氧化平衡中起到至关重要的作用。
血管紧张素转化酶(ACE)又称激肽酶Ⅱ或肽基-羧基肽酶,属血管内皮细胞膜结合酶。ACE主要功能有:催化血管紧张素Ⅰ转化为血管紧张素Ⅱ;使缓激肽失活。血管紧张素转化酶因这两种功能而成为治疗高血压等疾病的理想靶点。
γ-氨基丁酸(GABA)是一种四碳、非蛋白氨基酸,作为一种重要的抑制性神经递质,对哺乳动物具有安神、降低血压、改善睡眠等多种生理功能。有研究报道,GABA作为氧化代谢物的调控者发挥抗氧化作用,将拟南芥SSADH突变体暴露于高温下生长,发现其活性氧中间体(reactive oxygen intermediate,ROI)积累,使得植株死亡,而GABA可以减少ROI的积累使得生物免于高温带来的氧化损伤以及过氧化衰亡。
共轭亚油酸(CLA)是一系列双键亚油酸,具有清除自由基、增强人体的抗氧化能力和免疫能力、调节血液胆固醇和甘油三酸脂水平、防止动脉粥样硬化、促进脂肪氧化分解、对人体进行全面的良性调节等作用。有报道指出,CLA能有效的发挥“血管清道夫”的作用,可清除血管中的垃圾,有效调节血液黏稠度,扩张和松弛血管平滑肌、抑制血液运动中枢的作用,降低了血液循环的外周阻力,使血压下降,尤其是使舒张压下降更为明显,能够改善微循环、平稳血压。
B族维生素的抗氧化功效是众所周知的,B族维生素还可帮助清除肝脏脂肪,降低胆固醇,预防动脉硬化。此外,维生素B还能预防太阳晒伤及皮肤癌,保持皮肤光滑滋润,延迟皱纹的出现,还能促进毛发健康生长。有研究报道,B族维生素中的维生素B2、维生素B3、维生素B6等均不同程度参与机体氧化还原过程,在体内抗氧化防御系统中起着重要作用。
根据本发明的具体实施方案,本发明测量了K56发酵乳液的上清中超氧化物歧化酶、血管紧张素转化酶抑制物、γ-氨基丁酸、共轭亚油酸和/或B族维生素,发酵产物的上清液作为或进一步用于制备所述具有抗氧化、调节血压和/或调节睡眠功效的组合物。
根据本发明的一些具体实施方案,本发明的副干酪乳杆菌K56发酵乳液,总抗氧化能力(T-AOC)达到1.0~3.0U/mL,且随着发酵过程的进行总抗氧化能力下降缓慢。
根据本发明的一些具体实施方案,本发明的副干酪乳杆菌K56发酵乳液,总超氧化物歧化酶(T-SOD)活力可达20~30U/mL。
根据本发明的一些具体实施方案,本发明的副干酪乳杆菌K56发酵乳液,血管紧张素转化酶抑制率(ACE)可达10~70%。
根据本发明的一些具体实施方案,本发明的副干酪乳杆菌K56发酵乳液中,γ-氨基丁酸含量(GABA)可达14~21μg/mL。
根据本发明的一些具体实施方案,本发明的副干酪乳杆菌K56发酵乳液中,共轭亚油酸(CLA)可达0.01~0.06mg/kg。
根据本发明的一些具体实施方案,本发明的副干酪乳杆菌K56发酵乳液中,维生素B1含量可达30~70μg/mL;维生素B2含量可达2.8~3μg/mL;维生素B3为50~80μg/mL;维生素B6含量为8~20μg/mL;维生素B9的含量为1.6~1.8μg/mL。
根据本发明的具体实施方案,本发明的副干酪乳杆菌K56发酵乳基质所得到的发酵产物可以直接作为食品(例如发酵乳、乳饮品、奶粉、固体饮料等)、日化品(化妆品等)、饲料(包括宠物食品或畜牧用益生菌产品)或药物等,或是进一步用于制备这些食品、日化品、饲料或药物产品。以发酵产物制备食品、日化品、饲料或药物产品的方法可以参照所属领域中的现有技术进行。
在本发明的一具体实施方案中,本发明的K56发酵产物是作为或是进一步用于制备食品,所述食品优选为发酵乳或发酵乳饮料。作为发酵底物的乳液中还可包括发酵乳或发酵乳饮料中常用的其他原料,例如适量的甜味剂、稳定剂、营养添加剂等。所述的发酵乳或发酵乳饮料可以是低温保存的活性菌的发酵乳或发酵乳饮料,也可以是常温保存的灭菌的发酵乳或发酵乳饮料。在本发明的一些更具体实施方案中,所述发酵乳或发酵乳饮料中副干酪乳杆菌CGMCC No.15139的含量为1×107cfu/mL~1×1011cfu/mL。
综上所述,本发明提供了副干酪乳杆菌K56的新用途,本发明发现该菌株单菌发酵乳基质,能够产生超氧化物歧化酶、血管紧张素转化酶抑制物、γ-氨基丁酸、共轭亚油酸和B族维生素等物质,具有抗氧化、调节血压与调节睡眠的潜能。本发明的副干酪乳杆菌K56菌株可用于具有抗氧化、调节血压、调节睡眠功效的发酵乳、乳饮品、奶粉、固体饮料、日化品等生产应用。
具体实施方式
为了对本发明的技术特征、目的和有益效果有更加清楚的理解,现结合具体实施例及对本发明的技术方案进行以下详细说明,应理解这些实例仅用于说明本发明而不用于限制本发明的范围。实施例中,各原始试剂材料均可商购获得,未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件,或按照仪器制造商所建议的条件。
实施例1:副干酪乳杆菌K56发酵乳生长动力学特征测定
1、实验菌株
本发明技术方案所用副干酪乳杆菌K56(CGMCC No.15139);
对照菌株1:商业副干酪乳杆菌菌株L.CASEI 431;
对照菌株2:商业副干酪乳杆菌菌株LPC-37。
2、菌株的活化与种子液培养
(1)菌株活化:以MRS培养基活化副干酪乳杆菌,取生长至对数期的菌株,甘油管保存备用。其中,MRS培养基(g/L):蛋白胨10.0g;酵母膏5.0g;葡萄糖20.0g;无水乙酸钠5.0g;柠檬酸二氢胺2.0g;吐温-80 1.0mL;磷酸氢二钾2.0g;七水硫酸镁0.2g;硫酸锰0.05g;牛肉膏10.0g;琼脂15g-20g。
(2)菌株生长动力特征测定
12%全脂乳粉+6%白砂糖常温溶解于水中,于95℃条件下灭菌5min,降温至36℃±1℃,作为乳基质接种菌株后发酵培养120h,于不同的发酵时间段取样,测定活菌数及pH值。
活菌数检测:25ml样品与75ml生理盐水混合均匀后,平板稀释法计数。
酸度检测:使用pH计测定样品pH并记录。取10g发酵乳制品,加入2滴酚酞溶液混匀,0.1M标准NaOH溶液滴定至粉红色。滴定酸度计算公式:
°T=C×V×100/(m×0.1)。
测定结果分别参见表1和表2。
表1副干酪乳杆菌在乳基质中不同发酵时间的菌落计数
由以上测试数据分析可知,K56发酵的pH值在28h活菌数增长迅速,之后降低达到平稳。对照菌株1、对照菌株2在36h活菌数增长迅速,之后降低达到平稳。K56与对照菌株1、对照菌株2分析p>0.05,无显著差异;对照菌株1与对照菌株2分析p>0.05,无显著差异。其中空白组为不加菌液的乳基质。
表2副干酪乳杆菌在乳基质中不同发酵时间的pH测定
由以上测试数据分析可知,K56、对照菌株1、对照菌株2在12h~36h内逐渐下降。K56与对照菌株2分析p<0.01,有极显著差异;K56与对照菌株1分析p>0.05,无显著差异;对照菌株1与对照菌株2分析p>0.05,无显著差异。由于温度原因,空白组中含有未杀灭的微生物导致奶腐败变质,pH值下降。其中空白组为不加菌液的乳基质。
(3)菌株种子液的制备:12%全脂乳粉+6%白砂糖常温溶解于水中,于95℃条件下灭菌5min,降温至36℃±1℃,接种菌株后36℃±1℃发酵培养48h±2h,可延长至72h±2h,作为种子液。
3、副干酪乳杆菌发酵乳抗氧化能力检测
发酵乳制备:生牛乳,加入占生牛乳总重量6.5%的蔗糖,搅拌,加热至95℃、5min杀菌,杀菌后的乳液冷却到37℃,分别加入各菌种子液(副干酪乳杆菌K56接种量3%,对照菌接种量根据活菌数折算成与K56等量),各样品分别于37℃发酵24、48、72、96、120h,发酵乳在4℃以8000r/min离心15min,收集发酵上清液,过0.22μm滤膜,滤液进行抗氧化能力的测定。
(1)总抗氧化(T-AOC)能力测定
本发明中,副干酪乳杆菌抗氧化能力主要通过测定总抗氧化(T-AOC)能力来评价。
总抗氧化(T-AOC)能力测定采用购于南京建成的总抗氧化能力(T-AOC)检测试剂盒,操作按照试剂盒说明书进行。抗氧化物质能把三价铁离子还原成二价铁离子,后者可以和菲啉类物质形成稳固的络合物,通过比色法可测定出其抗氧化能力的高低。测定过程中,待测样品与试剂盒提供的试剂混合时,漩涡混匀器充分混匀,37℃水浴30分钟放置10分钟,波长520nm,1cm光径,双蒸水调零,测定各管吸光度值。
本发明中,不同发酵时间的益生菌发酵上清的T-AOC能力测定结果参见表3。
表3总抗氧化能力
(2)K56发酵样品中其他抗氧化相关能力的检测
本发明中,还检测了K56发酵样品中其他抗氧化相关能力,包括不同发酵时间的上清液的总超氧化物歧化酶(T-SOD)活力、血管紧张素转化酶抑制率(ACE)、超氧阴离子自由基清除能力、OH自由基清除能力、DPPH自由基清除能力、γ-氨基丁酸含量(GABA)、共轭亚油酸(CLA)、B族维生素含量。
本发明中,总超氧化物歧化酶(T-SOD)活力测定采用购于南京建成的总超氧化物歧化酶(T-SOD)试剂盒,操作按照试剂盒说明书进行。通过黄嘌呤及黄嘌呤氧化酶反应系统产生超氧阴离子自由基,后者氧化羟胺形成亚硝酸盐,在显色剂的作用下呈现紫红色,用可见分光光度计测其吸光度。当被测样品种含有SOD时,则对超氧阴离子自由基有专一性的抑制作用,使形成的亚硝酸盐减少,比色时测定管的吸光度值低于对照管的吸光度值,通过计算可求出样品中SOD的活力。
血管紧张素转化酶(ACE)测定方法主要有比色法、酶偶联法等。本发明中,用紫外分光光度法测定血管紧张素转化酶(ACE)抑制活性:取2mL的离心管,加入底物为5mmol/LHippuryl-His-Leu(HHL)为底物的50mmol/L硼酸钠缓冲液50μL,再加入20μL待测液体,混合,在37℃水浴中预热3min,加入10μL ACE酶液,在37℃反应30min,再加入100μL 1mol/L盐酸终止反应。加入1.7mL乙酸乙酯,震荡15s,3000×g离心10min,分离上层1mL乙酸乙酯层(样品所在层)。加热挥发除去有机溶剂,再加入1mL去离子水,并震荡使马尿酸完全溶解,用微量紫外分光光度法在228nm测定样品吸光值。ACE抑制率(ACEI)计算公式如下:
其中,A表示ACE与HHL反应完全生成马尿酸的吸光值(对照);B表示待测液体与ACE和HHL反应后生成马尿酸的吸光值(样品);C表示先加入盐酸ACE和HHL反应后生成马尿酸的吸光值。
本发明中,超氧阴离子自由基清除能力测定采用邻苯三酚-分光光度计法。邻苯三酚-分光光度法被广泛应用于食品和药品行业的抗氧化剂初步筛选及各种活性物质清除超氧阴离子自由基的抗氧化功能评价。邻苯三酚自氧化过程为链式反应,可产生超氧阴离子自由基,其自身氧化产物的含量可用分光光度仪检测,通过此法间接评价抗氧化物质的抗氧化能力。具体步骤:取0.88mL 0.1mol/L Tris-HCl缓冲液(pH 8.2)于试管中,依次加入0.2mL 1.0mmol/L乙二胺四乙酸(EDTA)、0.2mL样品、0.3mL蒸馏水。于25℃水浴反应10min,再加入0.4mL 9.0mmol/L邻苯三酚,准确反应60min后,加100μL 12.0mol/L HCl终止反应。以上均平行测定3次取平均值,并且重复实验3次。计算公式:清除率=(Ac-As)/Ac×100%,其中,As:在波长325nm处测定吸光度;Ac:空白管以0.2mL蒸馏水代替样品,操作方法同样品管,测得吸光度。
本发明中,OH自由基清除能力采用邻二氮菲法测定。
本发明中,γ-氨基丁酸(GABA)含量测定方法根据“QB/T 4587-2013γ-氨基丁酸”进行。
本发明中,共轭亚油酸(CLA)含量测定方法根据“乳及乳制品中共轭亚油酸(CLA)含量测定气相色谱法NY/T 1671-2008”进行。
本发明中,B族维生素含量采用高效液相色谱仪测定方法,具体操作条件参照“HPLC检测黑皮鸡枞菌中的水溶性维生素(李艳,《食品研究与开发》,2018)”进行。
本发明中,K56不同发酵时间的益生菌发酵上清的总超氧化物歧化酶(T-SOD)活力、血管紧张素转化酶抑制率(ACE)、超氧阴离子自由基清除能力、OH自由基清除能力、DPPH自由基清除能力、γ-氨基丁酸含量(GABA)、共轭亚油酸(CLA)、B族维生素测定结果参见表4。
表4 K56发酵上清相关抗氧化能力测定
由上述测定结果可知,K56发酵乳液具有优异的抗氧化能力,可用于具有抗氧化、调节血压、调节睡眠功效的发酵乳、乳饮品、奶粉、固体饮料、日化品等生产应用。
实施例2.副干酪乳杆菌K56发酵制备具有抗氧化、调节血压、调节睡眠潜力的乳饮料
本实施例提供了副干酪乳杆菌K56发酵制备的具有抗氧化、调节血压、调节睡眠潜力的乳饮料。该饮料的制作步骤如下:
(a)将副干酪乳杆菌K56接种于脱脂乳中进行发酵,发酵后得到发酵乳;
(b)利用甜味剂和/或酸味剂勾兑形成勾兑液,将勾兑液与步骤(a)制得的发酵乳混匀,均质,制备得到发酵乳饮料。
进一步地,所述步骤(a)中发酵的温度为37℃,发酵的时间为72h。
进一步地,步骤(b)中,所述发酵乳与勾兑液的混合体积比例为1:4。
进一步地,步骤(b)中均质的压力为30MPa。
进一步地,步骤(b)中可采用灭菌工艺,优选的灭菌的温度为120℃,灭菌的时间为15min。
本实施例的饮料在低温和常温两种产品品类中均具有良好的抗氧化、调节血压、调节睡眠的潜力。
Claims (9)
1.一种副干酪乳杆菌 (Lactobacillus paracasei subsp. paracasei)在制备具有抗氧化功效的组合物中的应用,所述副干酪乳杆菌的保藏编号为CGMCC No. 15139,其中:
利用副干酪乳杆菌CGMCC No. 15139发酵乳液,制备得到发酵产物,得到的发酵产物作为或进一步用于制备所述具有抗氧化功效的组合物;
其中所述乳液为生鲜牛乳或复原乳。
2.根据权利要求1所述的应用,其中,所述组合物为食品组合物、饲料组合物、化妆品组合物或药品组合物。
3.根据权利要求1所述的应用,其中,所述乳液中含有5%~10%的蔗糖。
4.根据权利要求1或3所述的应用,其中,所述发酵条件为:35℃~45℃,发酵1天~7天。
5.根据权利要求4所述的应用,其中,副干酪乳杆菌以种子液的形式接种于乳液中,接种量2%~5%。
6.根据权利要求1或3所述的应用,其中,发酵产物的上清液作为或进一步用于制备所述具有抗氧化功效的组合物。
7.根据权利要求1所述的应用,其中,所述具有抗氧化功效的组合物为发酵乳、发酵乳饮料或奶粉。
8.根据权利要求1所述的应用,其中,所述具有抗氧化功效的组合物为固体饮料。
9. 根据权利要求7所述的应用,其中,所述发酵乳或发酵乳饮料中副干酪乳杆菌CGMCCNo. 15139的含量为1×107 cfu/mL~ 1×1011 cfu/mL。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310062183.9A CN116035069A (zh) | 2020-11-26 | 2020-11-26 | 用于调节睡眠的副干酪乳杆菌k56及其应用 |
CN202011348882.2A CN113367191B (zh) | 2020-11-26 | 2020-11-26 | 用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 |
CN202310057188.2A CN116114758A (zh) | 2020-11-26 | 2020-11-26 | 用于调节血压的副干酪乳杆菌k56及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011348882.2A CN113367191B (zh) | 2020-11-26 | 2020-11-26 | 用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310057188.2A Division CN116114758A (zh) | 2020-11-26 | 2020-11-26 | 用于调节血压的副干酪乳杆菌k56及其应用 |
CN202310062183.9A Division CN116035069A (zh) | 2020-11-26 | 2020-11-26 | 用于调节睡眠的副干酪乳杆菌k56及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113367191A CN113367191A (zh) | 2021-09-10 |
CN113367191B true CN113367191B (zh) | 2022-11-29 |
Family
ID=77569069
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310057188.2A Pending CN116114758A (zh) | 2020-11-26 | 2020-11-26 | 用于调节血压的副干酪乳杆菌k56及其应用 |
CN202310062183.9A Pending CN116035069A (zh) | 2020-11-26 | 2020-11-26 | 用于调节睡眠的副干酪乳杆菌k56及其应用 |
CN202011348882.2A Active CN113367191B (zh) | 2020-11-26 | 2020-11-26 | 用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310057188.2A Pending CN116114758A (zh) | 2020-11-26 | 2020-11-26 | 用于调节血压的副干酪乳杆菌k56及其应用 |
CN202310062183.9A Pending CN116035069A (zh) | 2020-11-26 | 2020-11-26 | 用于调节睡眠的副干酪乳杆菌k56及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN116114758A (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113892651A (zh) * | 2021-10-08 | 2022-01-07 | 河北一然生物科技股份有限公司 | 一种复合益生菌制剂在抗氧化领域中的新应用 |
CN114686526A (zh) * | 2021-12-30 | 2022-07-01 | 广州君研生物科技有限公司 | 干酪乳杆菌发酵产物及包含干酪乳杆菌发酵产物的护肤品 |
CN115895973B (zh) * | 2022-07-20 | 2023-11-17 | 南京农业大学 | 一株副干酪乳杆菌及其在白酸汤发酵制备中的应用 |
CN115851520B (zh) * | 2022-11-09 | 2024-04-19 | 厦门元之道生物科技有限公司 | 一种副干酪乳杆菌及其应用 |
CN116444612A (zh) * | 2022-11-30 | 2023-07-18 | 内蒙古伊利实业集团股份有限公司 | 乳源活性肽apadpgrptgy及其制备方法与应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10406186B2 (en) * | 2015-01-31 | 2019-09-10 | Constance Therapeutics, Inc. | Cannabis oil extracts and compositions |
CN105368738A (zh) * | 2015-10-23 | 2016-03-02 | 中国农业大学 | 一种副干酪乳杆菌及其应用 |
CN106071436A (zh) * | 2016-06-12 | 2016-11-09 | 中国食品发酵工业研究院 | 一种能够改善睡眠质量的芦笋发酵饮品及其制备方法 |
WO2019010254A1 (en) * | 2017-07-07 | 2019-01-10 | President And Fellows Of Harvard College | METHOD OF TREATING A DAMAGE INDUCED BY SLEEP |
JP7041508B2 (ja) * | 2017-12-22 | 2022-03-24 | キリンホールディングス株式会社 | 概日リズム改善用組成物 |
CN110882280B (zh) * | 2019-06-27 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56的新应用 |
CN110892940A (zh) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56在缓解肠道炎症方面的新应用 |
CN110892914A (zh) * | 2019-11-20 | 2020-03-20 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56改善气喘及相关过敏性症状的新应用 |
-
2020
- 2020-11-26 CN CN202310057188.2A patent/CN116114758A/zh active Pending
- 2020-11-26 CN CN202310062183.9A patent/CN116035069A/zh active Pending
- 2020-11-26 CN CN202011348882.2A patent/CN113367191B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN116035069A (zh) | 2023-05-02 |
CN113367191A (zh) | 2021-09-10 |
CN116114758A (zh) | 2023-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113367191B (zh) | 用于抗氧化、调节血压的副干酪乳杆菌k56及其应用 | |
CN113349254B (zh) | 抗氧化、调节血压的副干酪乳杆菌et-22及其应用 | |
CN113773999B (zh) | 副干酪乳杆菌发酵滤液、制备方法及其应用 | |
CN113930361B (zh) | 一种副干酪乳杆菌的发酵培养基及其应用 | |
CN103649304B (zh) | 分离的微生物菌株植物乳杆菌(lactobacillus plantarum)mcc1 dsm 23881及其用途 | |
CN111471604B (zh) | 单胞酿酒酵母菌ZLG-6和植物乳杆菌Picp-2的应用 | |
CN113350383B (zh) | 抗氧化、调节血压的乳双歧杆菌bl-99及其应用 | |
CN113413351A (zh) | 一种具有美白抗衰功效的发酵液、发酵多肽及其制备方法和应用 | |
CN116286468A (zh) | 一株具有抗氧化功能的发酵粘液乳杆菌lf-onlly及其在发酵食品中的应用 | |
Rezaei et al. | Isolation of lactic acid probiotic strains from Iranian camel milk: technological and antioxidant properties | |
JP3973108B2 (ja) | アントシアニンを含有する低カロリー乳酸菌飲料の製造方法 | |
KR101091833B1 (ko) | 유산균을 이용한 sac 고함량 마늘 발효물의 제조방법 | |
Padghan et al. | Studies on bio-functional activity of traditional Lassi | |
KR20190044166A (ko) | 항산화 및 항피로 효능을 갖는 매실식초의 제조방법 | |
US10307445B2 (en) | Bacterial strains having an outstanding ability to produce menaquinone | |
Long et al. | Free radical scavenging ability of soybean milk fermented by Lactobacillus plantarum YS4 isolated from yak yoghurt in vitro | |
CN112167345B (zh) | 含抗氧化的乳酸菌发酵物的食品组合物以及医药组合物 | |
CN113632922A (zh) | 一种溶胞物、以及制备方法与应用 | |
CN111500642B (zh) | 一种蓝莓发酵产物及其制备方法和应用 | |
TWI824330B (zh) | 經乳酸菌發酵之嘉寶果萃取物及其製備方法 | |
CN117223808B (zh) | 一种高产γ-氨基丁酸的二联活菌发酵饮料 | |
TWI752334B (zh) | 含抗氧化之乳酸菌發酵物之食品組合物以及醫藥組合物 | |
TWI742406B (zh) | 用以抗氧化之含乳酸菌菌株之食品組合物以及醫藥組合物 | |
KR20220028782A (ko) | 항산화 및 항비만 효능을 갖는 산수유 유산균 발효 조성물 및 이의 제조 방법 | |
CN117946939A (zh) | 一株植物乳植杆菌sm2及其在制备降胆固醇和助睡眠食品药品中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |